These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 17286215)

  • 1. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis.
    Kudo-Tanaka E; Ohshima S; Ishii M; Mima T; Matsushita M; Azuma N; Harada Y; Katada Y; Ikeue H; Umeshita-Sasai M; Miyatake K; Saeki Y
    Clin Rheumatol; 2007 Oct; 26(10):1627-33. PubMed ID: 17286215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
    Lakos G; Soós L; Fekete A; Szabó Z; Zeher M; Horváth IF; Dankó K; Kapitány A; Gyetvai A; Szegedi G; Szekanecz Z
    Clin Exp Rheumatol; 2008; 26(2):253-60. PubMed ID: 18565246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis.
    Hiura K; Iwaki-Egawa S; Kawashima T; Fujisawa S; Takeda T; Komori H; Watanabe Y
    Rheumatol Int; 2013 Sep; 33(9):2309-14. PubMed ID: 23503938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.
    Abdel-Nasser AM; Mahmoud MH; El Mansoury TM; Osman AM
    Scand J Rheumatol; 2008; 37(5):329-36. PubMed ID: 18666028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
    Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
    Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of anti-CCP2 and RF isotypes and their relation to age and disease severity among Sudanese patients with rheumatoid arthritis.
    Elshafie AI; Elbagir S; Aledrissy MIE; Elagib EM; Nur MAM; Rönnelid J
    Clin Rheumatol; 2019 Jun; 38(6):1545-1553. PubMed ID: 30656490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic performance of anti-cyclic citrullinated antibodies and IgM rheumatoid factor in rheumatoid arthritis].
    Lemos A; Ramos MP; Furtado MJ; Carvalho C; Santos MJ; Silva JC; Ventura H
    Acta Reumatol Port; 2007; 32(4):345-9. PubMed ID: 18159201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X; Jia R; Zhao J; Li Z
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.
    Jaskowski TD; Hill HR; Russo KL; Lakos G; Szekanecz Z; Teodorescu M
    J Rheumatol; 2010 Aug; 37(8):1582-8. PubMed ID: 20516016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor.
    Yamane T; Hashiramoto A; Tanaka Y; Tsumiyama K; Miura Y; Shiozawa K; Chihara K; Shiozawa S
    J Rheumatol; 2008 Mar; 35(3):414-20. PubMed ID: 18203327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis.
    van Gaalen FA; Visser H; Huizinga TW
    Ann Rheum Dis; 2005 Oct; 64(10):1510-2. PubMed ID: 15800005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios.
    Pietrapertosa D; Tolusso B; Gremese E; Papalia MC; Bosello SL; Peluso G; Petricca L; Michelutti A; Faustini F; Fedele AL; Ferraccioli G
    Clin Chem Lab Med; 2010 Jun; 48(6):829-34. PubMed ID: 20298138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins.
    Hensvold AH; Frisell T; Magnusson PK; Holmdahl R; Askling J; Catrina AI
    Ann Rheum Dis; 2017 Jan; 76(1):119-125. PubMed ID: 27125521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.
    van Gaalen FA; Linn-Rasker SP; van Venrooij WJ; de Jong BA; Breedveld FC; Verweij CL; Toes RE; Huizinga TW
    Arthritis Rheum; 2004 Mar; 50(3):709-15. PubMed ID: 15022309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibrin-derived citrullinated peptide β60-74Cit₆₀,₇₂,₇₄ bears the major ACPA epitope recognised by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies.
    Cornillet M; Sebbag M; Verrouil E; Magyar A; Babos F; Ruyssen-Witrand A; Hudecz F; Cantagrel A; Serre G; Nogueira L
    Ann Rheum Dis; 2014 Jun; 73(6):1246-52. PubMed ID: 23636655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
    Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M
    Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis.
    Besada E; Nikolaisen C; Nossent H
    Clin Exp Rheumatol; 2011; 29(1):85-8. PubMed ID: 21269572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.